MLTX
MoonLake Immunotherapeutics
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
MoonLake Immunotherapeutics
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
MoonLake Immunotherapeutics
11.78
No N-PORT holders.
No thesis.
Largest filed tie
—
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | BVFBVF | $311.5M | 21.27% | 0.00% | |
| 2 | Deep Track CapitalDeep Track Capital | $136.3M | 9.30% | +9.21% | |
| 3 | T. Rowe Price Investment ManagementT. Rowe Price | $83.3M | 5.69% | new | |
| 4 | D. E. ShawD. E. Shaw | $65.5M | 4.47% | +40.78% | |
| 5 | Cormorant Asset ManagementCormorant | $62.4M | 4.26% | −28.46% | |
| 6 | Jupiter TopcoJupiter Topco | $60.1M | 4.10% | — | |
| 7 | Logos Global ManagementLogos Global | $52.1M | 3.56% | +78.33% | |
| 8 | Weiss Asset ManagementWeiss | $50.3M | 3.43% | +51.13% | |
| 9 | Citadel AdvisorsCitadel | $47.9M | 3.27% | +18.07% | |
| 10 | Two Sigma InvestmentsTwo Sigma | $33.4M | 2.28% | +52.84% | |
| 11 | MPM Oncology Impact ManagementMPM Oncology Impact | $31.3M | 2.14% | −11.27% | |
| 12 | JPMorgan ChaseJPMorgan Chase | $27.6M | 1.88% | +27.37% | |
| 13 | Vivo CapitalVivo Capital | $27.3M | 1.86% | +40.00% | |
| 14 | Jane Street GroupJane Street | $22.8M | 1.55% | +104.27% | |
| 15 | Point72 Asset ManagementPoint72 | $22.6M | 1.54% | −15.33% | |
| 16 | BlackRockBlackRockindex-like | $21.3M | 1.46% | +7.14% | |
| 17 | T. Rowe Price AssociatesT. Rowe Price | $20.3M | 1.38% | −19.56% | |
| 18 | Balyasny Asset ManagementBalyasny | $17.8M | 1.21% | −14.35% | |
| 19 | Great Point PartnersGreat Point Partners | $16.7M | 1.14% | +71.16% | |
| 20 | Candriam Luxembourg S.C.A.Candriam Luxembourg S.C.A. | $15.0M | 1.02% | −5.91% | |
| 21 | Bank of AmericaBank of America | $14.6M | 1.00% | +3.74% | |
| 22 | Arrowstreet Capital, Limited PartnershipArrowstreet Capital, Limited Partnership | $14.6M | 1.00% | +970.40% | |
| 23 | Trails Edge Capital PartnersTrails Edge Capital Partners | $14.6M | 1.00% | new | |
| 24 | Susquehanna International GroupSusquehanna International | $14.0M | 0.96% | −40.43% | |
| 25 | HRT FinancialHRT Financial | $13.2M | 0.90% | +39.31% |
175 managers report $1.5B of MoonLake Immunotherapeutics on form 13F for the quarter ended Jun 30 '26. 24 of them hold 80% of it; BVF is largest at 21.27%.
Expected move
Inputsspot 11.78exp Nov 20ATM strike 12ATM straddle 2.18IV 95%